Our PROPHETIC trial was one of the most talked about trials by the top influencers at #AACR24 📢 Thank you @larvol for compiling and sharing this data.
x.com/Larvol/status/…
#cancerresearch #AI #NSCLC #biomarkers
In company of Dr Yi-Long Wu, Dr Thanyanan Baisamut (Reungwetwattana) & Dr Tony Mok. A much needed asian perspective on thoracic oncology. #NSCLC #LungCancer #Esmo #IASLC #AdvancedCourse #HongKong
Excellent presentation by Melissa L. Johnson on KRAS G12C in NSCLC at #TexasLung24 discussing the data available on the landscape.
Stephen V Liu, MD #TinaCascone
KRASKickers
Some advances for our BRAF V600E NSCLC patients…Review to read at npj Journals - d.planchard
#Cancer #LungCancer #NSCLC #OncoDaily #Oncology #Cancer Research #Cancer Treatment
oncodaily.com/51702.html
I believe that such an updatable tool provides crucial support for optimal #TreatmentDecisionMaking in pts with non-oncogene addicted metastatic #NSCLC and PDL1 over 50%, plus #brainmets . #IAmAPractisingOncologist & I use #ESMOLivingGuidelines . @myesmo RADU VIDRA Mila Petrova
New Treatment Approved for Early-Stage ALK+ #LungCancer .
#Alectinib is now approved to treat patients after surgical removal of ALK-positive non-small cell lung cancer (NSCLC). Learn more by visiting the ALK+ Lung Cancer Patient Gateway: bit.ly/3UvK6zW #lcsm
Getting two plenaries from one track (early stage NSCLC /meso/ sclc) and 3 plenaries in Lung Ca !!! Super thrilled to have been part of the track that might have just created history !!! Patrick Forde Shankar Siva Melina Marmarelis Lecia Sequist, MD, MPH Lynn M. Schuchter, MD, FASCO Angie DeMichele, MD, MSCE, FASCO
9th TNM Staging for Lung Cancer by Dr. Hisao Asamura, chair of IASLC's Staging and Prognostic Factors Committee and highlighting Dr Valerie Rusch’s 10th edition of TNM which should come in 2031 #NSCLC #LungCancer #Esmo #IASLC #AdvancedCourse #Osimertinib #ResidentLife #HongKong
Don't miss AstraZeneca's lunch symposium on Monday, Apr 29 featuring Daniela, Jonathan Spicer MD PhD, Erin Gillaspie, and Krish Bhadra. #NSCLC #AATS2024
Dr. Gʀᴇɢᴏʀʏ Rɪᴇʟʏ discusses adjuvant targeted therapy approaches in resectable NSCLC at #TexasLung24 . For pts with EGFRm and ALKm this has been transformative. Interesting to see how this can be applied to other drivers now and perhaps off label currently??
Evidence-based guidance on the management of unresectable locally advanced #NSCLC non-small cell #lungcancer scenarios is provided by the American Radium Society Appropriate Use Criteria (AUC) Thoracic Committee to optimize multiD patient care for #lcsm .
🫁jamanetwork.com/journals/jamao…
